Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy

Mieke Kriege, Antoinette Hollestelle, Agnes Jager, PEA Huijts, EM Berns, Anieta Sieuwerts, Marion Gelder, Margriet Collee, P Devilee, Maartje Hooning, John Martens, Caroline Seynaeve

Research output: Contribution to journalArticleAcademicpeer-review

52 Citations (Scopus)
9 Downloads (Pure)


Background: We assessed the sensitivity to adjuvant chemotherapy in cell cycle checkpoint kinase 2 (CHEK2) vs non-CHEK2 breast cancer patients by comparing the contralateral breast cancer incidence and distant disease-free and breast cancer-specific survival between both groups, stratified for adjuvant chemotherapy. Methods: One Dutch hereditary non-BRCA1/2 breast cancer patient cohort (n = 1220) and two Dutch cohorts unselected for family history (n 1014 and n 2488, respectively) were genotyped for CHEK2 1100delC. Hazard ratios for contralateral breast cancer, distant disease-free and breast cancer-specific death for mutation carriers vs noncarriers were calculated using the Cox proportional hazard method, stratified for adjuvant chemotherapy. Results: The CHEK2 mutation carriers (n 193) had an increased incidence of contralateral breast cancer (multivariate hazard ratio 3.97, 95% confidence interval 2.59-6.07). Distant disease-free and breast cancer-specific survival were similar in the first 6 years in mutation carriers compared with noncarriers, but diverted as of 6 years after breast cancer diagnosis (multivariate hazard ratios and 95% confidence intervals 2.65 (1.79-3.93) and 2.05 (1.41-2.99), respectively). No significant interaction between CHEK2 and adjuvant chemotherapy was observed. Conclusions: The CHEK2 1100delC-associated breast cancer is associated with a higher contralateral breast cancer rate as well as worse survival measures beyond 6 years after diagnosis. No differential sensitivity to adjuvant chemotherapy was observed in CHEK2 patients.
Original languageUndefined/Unknown
Pages (from-to)1004-1013
Number of pages10
JournalBritish Journal of Cancer
Issue number5
Publication statusPublished - 2014

Research programs

  • EMC MM-03-86-01

Cite this